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Introduction
Language  is  a  quintessential  human  trait  that,  for  the 
most part, proceeds along a recognized trajectory with 
minimal explicit instruction [1]. In some cases, however, 
language  acquisition  is  not  so  straightforward  and 
language  ability  is  delayed  or  permanently  impaired. 
Some  times these impairments form part of a recognized 
medical  condition  (such  as  learning  deficit,  autism  or 
deafness), but often no obvious cause can be identified. 
In such cases, the language deficit is usually classified as 
specific language impairment (SLI) [2]. As such, SLI is 
usually  diagnosed  through  exclusionary  criteria  rather 
than on the basis of any specific clinical test. SLI affects 
between 5% and 8% of English-speaking (primarily UK 
and US) pre-school children, and is a lifelong disability 
with  an  increased  risk  of  behavioral  disorders,  social 
problems and literacy deficits [3-5]. The disorder shows 
significant overlap with associated developmental condi-
tions,  such  as  attention  deficit  hyperactivity  disorder 
(ADHD),  speech  sound  disorder  (SSD),  dyslexia  and 
autism [6].
Over  the  past  decade,  researchers  have  begun  to 
identify genetic factors that may have roles in the etiology 
of language disorders. It is hoped that the study of these 
genes will facilitate a better understanding of the cause of 
language  impairments,  leading  to  the  development  of 
improved diagnostic and treatment strategies for affected 
individuals.  In  turn,  knowledge  regarding  the  cause  of 
such impairments may further our understanding of the 
biological  pathways  that  underpin  normal  language 
acquisition [7].
Here, we focus on specific genes that have been identi-
fied  to  have  a  role  in  language  impairment.  Genetic 
link  age and association studies of SLI and related learn-
ing disorders are reviewed elsewhere [8-10].
FOXP2
Until  recently,  the  only  gene  that  had  been  directly 
implicated in the etiology of speech and language dis-
orders was the FOXP2 gene on chromosome 7q (OMIM 
605317).  In  2001,  a  study  by  Lai  and  colleagues  [11] 
implicated mutation of FOXP2 in a monogenic form of 
speech and language disorder found in a three-generation 
pedigree (the KE family) and in an unrelated individual 
with  a  chromosome  translocation.  In  both  cases,  the 
disorder  was  characterized  by  verbal  (or  articulatory) 
dyspraxia, that is, difficulties controlling the movement 
and sequencing of orofacial muscles, causing deficits in 
the production of fluent speech. In-depth studies of the 
KE  family  showed  that,  in  these  individuals,  speech 
production  problems  are  accompanied  by  a  complex 
array of linguistic deficits that include varying degrees of 
expressive and written language problems and, in some 
members, nonverbal cognitive impairments [12]. Subse-
quent screening studies have shown that although FOXP2 
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typical forms of SLI [13,14], heterozygous disruptions of 
this gene (point mutations or chromosomal rearrange-
ments) invariably lead to syndromes that include aspects 
of verbal dyspraxia [15-21].
The  FOXP2  gene  encodes  a  transcription  factor  that 
regulates  the  expression  of  other  genes.  Downstream 
target  screening  studies  have  highlighted  a  variety  of 
genes that may be regulated by FOXP2 and indicate that 
the effect of FOXP2 can vary greatly between tissues and 
developmental time points [22-24]. FOXP2 may thus be 
involved in a variety of biological pathways and cascades 
that  may  ultimately  influence  language  development. 
Path  way  analyses  of  the  identified  targets  indicate  an 
enrichment  of  genes  involved  in  the  functioning, 
develop  ment  and  patterning  of  the  central  nervous 
system.  In  analyses  of  human  neuronal  cell  models, 
Vernes et al. [23] estimated that FOXP2 may bind directly 
to  approximately  300  to  400  gene  promoters  in  the 
human  genome.  Although  statistically  significant  over-
laps were seen between the individual studies of FOXP2 
targets, there were also notable differences in the sets of 
downstream  genes  that  were  identified.  This  finding 
demonstrates  the  complexity  of  these  regulatory  path-
ways  and  the  inherent  difficulties  of  precisely  defining 
them in the laboratory.
FOXP2 in the brain
The expression of FOXP2 is not limited to the brain but is 
also seen in several other organs, primarily those derived 
from  the  foregut  endoderm,  such  as  the  lungs  and 
esophagus [25]. In the human brain, FOXP2 is expressed 
in a range of regions, including sensory and limbic nuclei, 
the cerebral cortex and several motor structures, particu-
larly the striatum and cerebellum [26,27]. Within these 
anatomical areas, FOXP2 expression is often limited to 
selected subdivisions or neuron types (for example, deep 
layers  of  the  cortex,  medium  spiny  neurons  in  the 
striatum and Purkinje cells in the cerebellum).
Mice that are bred to carry disruptions of both copies 
of Foxp2 survive only a few weeks. They are small for 
their  age  and  have  widespread  developmental  delays, 
severe  motor  abnormalities  and  impaired  cerebellar 
growth  [28-32].  Given  that  total  absence  of  functional 
Foxp2  results  in  lethality,  in-depth  behavioral  investi-
gations  have  focused  on  heterozygous  mouse  models, 
which carry a single working copy of Foxp2. Note that 
this  matches  the  heterozygous  state  of  humans  with 
FOXP2  mutations;  no  humans  carrying  homozygous 
mutations  have  ever  been  identified.  In  general,  it  is 
found that these animals have normal motor skills and no 
obvious  gross  abnormalities.  However,  in-depth  beha-
vioral and morphological profiling has uncovered subtle 
deficits.  Interestingly,  two  groups  have  reported  that 
heterozygous  pups  produce  fewer  innate  ultrasonic 
vocalizations  than  wild-type  animals  [28,30].  Other 
groups  have  questioned  the  reliability  of  this  finding, 
instead  describing  deficits  in  motor  skill  learning  [31], 
abnormal  synaptic  plasticity  in  striatal  and  cerebellar 
neural circuits [31] and differences in auditory brainstem 
responses [32] in heterozygous pups. In song-birds, it has 
been reported that reducing the expression of FoxP2 in 
an  area  of  the  brain  necessary  for  vocal  learning  can 
interfere with the song learning process [33]. For an in-
depth discussion of these animal studies, see [34].
Brain imaging studies of KE family members have also 
revealed structural and functional abnormalities in the 
cerebellum and striatum [12,35,36]. Affected individuals 
were found to have reduced gray matter densities in the 
caudate  nucleus,  the  cerebellum,  the  inferior  frontal 
gyrus  and  the  lower  primary  motor  cortex  [12,35]. 
During  the  performance  of  language-related  tasks,  in 
contrast  to  the  expected  left-lateralized  pattern  of 
activation,  affected  members  of  the  KE  family  showed 
bilateral, diffuse activation with little or no activity in the 
left inferior frontal cortex (which includes Broca’s area, 
involved in speech production) and reduced activation in 
other  speech-related  cortical  and  sub-cortical  brain 
regions.  In  addition,  brain  areas  not  usually  activated 
during linguistic tasks, including the posterior parietal, 
occipital and postcentral regions, were found to be over-
activated in affected individuals [36].
Evolution of FOXP2
Because of the proposed function of FOXP2 in speech 
and  language  development,  this  gene  has  been  widely 
investigated from an evolutionary perspective. Versions 
of FOXP2 are found in many organisms and show striking 
similarities in terms of sequence and expression patterns 
across vertebrate species [26,27,33,37-39]. Aside from a 
difference in polyglutamine tract length, there are only 
three  coding  changes  between  the  mouse  and  human 
versions of the FOXP2 gene, making it one of the most 
highly conserved genes found in comparisons of human-
rodent genomes [38,39]. Interestingly, analyses of primates 
demonstrated that two of these three changes occurred 
in the human lineage after splitting from the chimpanzee 
and  found  additional  signs  that  FOXP2  may  have 
undergone  accelerated  evolution  in  humans  [38,39]. 
Popu  lation modeling estimated that the gene was subject 
to positive selection approximately 200,000 years ago, a 
period  that  coincides  with,  or  is  subsequent  to,  the 
emergence  of  modern  humans  [38,39].  Note,  however, 
that  the  errors  attached  to  these  estimates  are  large. 
More  over,  subsequent  sequencing  of  paleontological 
samples  has  identified  the  human-specific  coding 
changes of FOXP2 in Neanderthal tissues, which suggests 
a more ancient origin, given that Neanderthals split from 
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interpretation of these data is still under debate [41].
Two studies have investigated the functional differences 
between the human version of FOXP2 and that found in 
the  chimpanzee.  Enard  et  al.  [42]  reported  that  when 
human-specific coding changes were engineered in mice 
(partially ‘humanizing’ them at the locus), this resulted in 
an altered structure of innate pup vocalizations, decreased 
levels of exploration, decreased levels of dopamine in the 
brain  and  an  increased  dendrite  length  and  synaptic 
plasticity in the striatum. These findings are intriguing, 
given  that  mice  carrying  disrupted  versions  of  Foxp2 
(described  above)  showed  contrasting  alterations  in 
similar developmental areas. Konopka et al. [24] investi-
gated  potential  differences  in  the  functionality  of  the 
human  and  chimpanzee  versions  of  FOXP2  [24].  They 
identified  116  genes  that  were  differentially  expressed 
between neuronal cell lines engineered to express either 
the human or the chimpanzee protein. They postulated 
that the identified set of genes may represent a biological 
network that could have a role in the evolution of human 
language,  noting  that  the  identified  targets  included 
genes involved in cerebellar motor function, craniofacial 
formation, cartilage and connective tissue formation [24].
In  conclusion,  although  the  exact  contributions  of 
FOXP2  to  the  development  of  speech  and  language 
remain unclear, the consensus from expression studies, 
neuro-imaging data and animal models is that this gene is 
of particular importance in the central nervous system, 
such that its dysfunction disturbs the development and 
function of the motor cortex, striatum and cerebellum. 
Investigations  of  the  properties  of  FOXP2  and  its 
downstream targets are beginning to identify networks of 
genes that could be crucial players in neural circuits that 
facilitate language acquisition.
CNTNAP2
The CNTNAP2 gene on chromosome 7q (OMIM 604569) 
was  the  first  gene  to  be  associated  with  genetically 
complex  forms  of  SLI.  This  association  was  achieved 
through  a  candidate  gene  approach  that  arose  from 
downstream  target  screening  studies  of  FOXP2  [43]. 
Vernes et al. [43] discovered that FOXP2 directly binds a 
regulatory region of the CNTNAP2 gene. CASPR2, the 
protein  encoded  by  CNTNAP2,  is  a  member  of  the 
neurexin family, a family that is particularly interesting 
from a functional point of view as members are known to 
interact with neuroligins to adhere presynaptic neuronal 
membranes to postsynaptic ones. In the case of CASPR2, 
the protein mediates interactions between neurons and 
glia  during  nervous  system  development  and  is  also 
involved  in  localization  of  potassium  channels  within 
differentiating axons [44,45]. Furthermore, both neurexins 
and neuroligins have been strongly implicated in autistic 
disorder,  a  neurodevelopmental  condition  that  shows 
strong overlap with SLI [46-52].
The regulation of CNTNAP2 by FOXP2 was verified 
both in neuronal cell lines and in vivo (in human fetal 
cortical slices). In both of these experiments, the level of 
FOXP2 was found to be inversely correlated with that of 
CASPR2 [43]. An association analysis of 38 single nucleo-
tide  polymorphisms  (SNPs)  across  CNTNAP2  was 
per  formed  in  184  families  ascertained  by  the  SLI 
Consortium  (SLIC).  These  families  were  identified  by 
various  different  groups  from  across  the  UK  but  all 
contained a proband who, currently or in the past, had 
expressive and/or receptive language abilities more than 
2 standard deviations (SD) below that expected for their 
age [53]. In accordance with SLI diagnostic guidelines, 
individuals with autistic features, signs of mental retarda-
tion or co-occurring medical conditions were excluded 
from  this  cohort.  Three  quantitative  measures  of 
language were considered in this group; composite scores 
of expressive and receptive language ability were derived 
from the Clinical Evaluation of Language Fundamentals 
battery  (CELF-R)  [54].  In  addition,  a  measure  of  non-
word repetition [55] was collected for all probands and 
siblings. This test involves the repetition of nonsensical 
words of increasing length and complexity and the results 
from  it  have  been  shown  to  be  highly  heritable  and  a 
consistent  marker  of  the  presence  of  language  impair-
ment. Non-word repetition is considered to be a measure 
of  phonological  short-term  memory,  leading  to  the 
proposal that short-term memory deficits may underlie 
some aspects of language impairment (reviewed in [56]). 
Nine  single  SNPs  in  CNTNAP2  showed  association 
primarily  with  the  non-word  repetition  phenotype  but 
also  with  expressive  and  receptive  language  measures. 
The  most  strongly  associated  SNP  was  rs17236239 
(P = 5.0 × 10-5), a variant that falls within an intronic 
sequence near the middle of the gene. This same region 
has  also  been  implicated  in  a  quantitative  language-
related trait (age at first word) in autism [57]. The exact 
mechanism by which the identified SNPs alter CNTNAP2 
function has yet to be elucidated, but the integration of 
evidence  from  these  various  routes  of  investigation 
makes CNTNAP2 a compelling candidate for language 
disorders.
The CNTNAP2 gene has recently been implicated in 
multiple neurodevelopmental disorders, including Gilles 
de la Tourette syndrome [58], schizophrenia [59], epilepsy 
[59,60],  autism  [57,61-65],  ADHD  [66]  and  mental 
retardation [45] (Table 1). This diverse range of studies 
provides  evidence  for  the  disruption  of  CNTNAP2  by 
copy  number  variants  (CNVs),  gross  chromosomal 
rearrangements and mutations as well as association with 
common variants. It remains unclear how one gene can 
contribute to such an array of neurological conditions, 
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are  not  completely  disparate  and  can  be  expected  to 
involve some shared neuropathology. Nonetheless, it is 
obvious that CNTNAP2 must have vital roles in neuronal 
development and that perturbations of the function of 
this gene significantly increase the chances of some form 
of neurological dysfunction. It is likely that the differences 
in  outcome  are  decided  by  a  complex  function  that 
includes the nature of the mutation and both the genetic 
and environmental background of the affected individual. 
For example, it is feasible to consider that gene deletions 
may have different effects from point mutations, and that 
the consequence of a point mutation will vary according 
to  its  location  in  the  protein  or  its  effect  on  gene 
expression. Equally, one can see how different combina-
tions of point mutations or common variants across gene 
networks may have divergent outcomes that depend on 
the exact genes involved.
It is likely that a gene such as CNTNAP2 functions in 
overlapping and intersecting neurodevelopmental path-
ways and thus even a seemingly subtle disruption of its 
function may affect a variety of processes. The eventual 
outcome at the organ or organism level may in turn be 
modulated  by  the  ability  of  downstream  genes  and 
proteins  to  compensate  for  these  variations.  We  can 
therefore  view  CNTNAP2  as  a  neuronal  buffer;  subtle 
disruptions of this gene alone may be insufficient to cause 
disorder  but  may  place  a  critical  load  on  neurological 
systems, which manifest in different ways depending on 
the  nature  of  additional  load  factors.  Once  a  critical 
threshold of load is exceeded, it is likely that neurological 
imbalance will ensue.
ATP2C2 and CMIP
The  calcium-transporting  ATPase  2C2  (ATP2C2)  and 
c-MAF inducing protein (CMIP) genes, both on chromo-
some  16q,  were  identified  as  SLI  candidates  by  a 
positional cloning approach, which involved a genome-
wide linkage study followed by a targeted high-density 
association  investigation  [53,67-70].  These  phased 
investigations were performed using the SLIC sample, as 
described above [53]. Genome-wide linkage analyses in 
these  families  revealed  a  strong  and  consistent  linkage 
signal on chromosome 16q with a measure of non-word 
repetition  [53,67-69].  Association  analyses  of  chromo-
some  16q  indicated  significant  association  with  two 
clusters of SNPs, one between exons 2 and 5 of the CMIP 
gene  (most  significant  P  =  5.5  ×  10-7)  and  another 
3 megabases distal between exons 7 and 12 of ATP2C2 
(most significant P = 2.0 × 10-5) [69]. Individuals carrying 
risk alleles at both these loci had an average non-word 
repetition  score  more than 1  SD  below  those  carrying 
homozygous  non-risk  alleles.  Association  between 
ATP2C2  and  performance  on  the  non-word  repetition 
Table 1. Investigations implicating CNTNAP2 in neurological disorders
Study  Trait  Gene disruption
Vernes et al. 2008 [43]  SLI  None - association with common variants; candidate gene association study
Zweier et al. 2009 [45]  Mental retardation with seizures   Homozygous deletion in a single sib pair; point mutation in a single proband
  (resembling Pitt-Hopkins syndrome)
Alarcón et al. 2008 [57]  Autism; quantitative measure of   None - association with common variants; positional mapping of chromosome 7
  ‘age at first word’  linkage region
Verkerk et al. 2003 [58]  Gilles de la Tourette syndrome with   Complex chromosome rearrangement in a single family
  obsessive compulsive disorder and  
  mental retardation
Friedman et al. 2008 [59]  Epilepsy and schizophrenia   Deletion in three unrelated individuals
  (one patient had autistic features and  
  mental retardation)
Strauss et al. 2006 [60]   Cortical dysplasia, focal epilepsy,   Point mutation; homozygosity mapping in isolated population
  relative macrocephaly and  
  diminished deep-tendon reflexes
Arking et al. 2008 [61]  Autism  None - association with common variants; genome-wide association
Bakkaloglu et al. 2008 [62]  Autism  Inversion - single patient; coding changes - mutation screen in patient cohort
Rossi et al. 2008 [63]  Autism and primary amenorrhea  Deletion - single patient
Poot et al. 2009 [65]  Autism  Complex chromosome rearrangement in a single individual
Elia et al. 2009 [66]  ADHD  Copy number variant - hemizygous deletion in a single proband
Terracciano et al. 2008 [80]  Openness to experience - the   None - association with common variants; genome-wide association of personality
  tendency to be imaginative, creative,   dimensions 
  unconventional, emotionally and  
  artistically sensitive; agreeableness
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sample selected from a population cohort (most signi  fi-
cant  P  =  0.006)  [69].  In  this  replication  sample,  some 
association  was  also  observed  with  CMIP  but  in  an 
opposite direction to that seen in the discovery cohort 
(most significant P = 0.02) [69]. Although this does not 
preclude the presence of a genuine association, as it may 
be  caused  by  differences  in  linkage  disequilibrium 
patterns,  it  does  highlight  the  need  for  careful  inter-
pretation of this result as well as for further replication in 
additional cohorts.
Both ATP2C2 and CMIP show expression in the brain 
and,  although  little  is  known  about  their  role  in  this 
tissue,  hypothetical  links  can  be  made  between  their 
putative  functions  and  language  and  memory-related 
processes. The CMIP protein forms part of the cellular 
scaffold linking the plasma membrane to the cytoskeleton 
[71],  and  cytoskeletal  remodeling  represents  a  critical 
step  in  neuronal  migration  and  synaptic  formation 
processes. In addition, CMIP has been shown to interact 
with filamin A and nuclear factor κB, both of which have 
important  neurological  functions  [72,73].  ATP2C2  is 
responsible for the removal of calcium and manganese 
from the cytosol into the Golgi body [74]. Calcium is an 
important  ion  in  the  regulation  of  many  neuronal 
processes, including working memory, synaptic plasticity 
and neuronal motility [75], and manganese dysregulation 
has been linked to neurological disorders [76]. Interest-
ingly, in a recent meta-analysis of genetic data for ADHD, 
which shows significant co-morbidity with SLI, chromo-
some 16q was highlighted as the most consistently linked 
region for this disorder [77]. Concurrent genome-wide 
association studies described significant association with 
a  variant  in  ATP2C2  [78],  reinforcing  the  fact  that,  as 
discussed above, the correlation between genetic suscep-
tibility and surface phenotype is far from straightforward.
As with CNTNAP2, the specific causal variants and the 
underlying  mechanisms  by  which  ATP2C2  and  CMIP 
might contribute to language impairment have yet to be 
elucidated. The characterization of these factors will not 
only provide definitive evidence for the involvement of 
these  genes  but  may  also  lead  to  the  identification  of 
further neurological pathways that contribute to language 
acquisition.  Given  the  proposed  reliance  of  non-word 
repetition  performance  on  short-term  memory  ability, 
one can postulate that the investigation of ATP2C2 and 
CMIP may provide a biological link between memory-
related pathways and language acquisition. The fact that 
neither  ATP2C2  nor  CMIP  have  been  identified  as 
downstream targets of FOXP2 suggests that the eventual 
combination  of  information  from  converging  routes  of 
investigation  will  enable  the  characterization  of  over-
lapping and interacting neurological systems that serve 
the acquisition of language.
Conclusions
The  past  few  years  have  seen  exciting  progress  in  the 
genetics of language impairment. The increased know-
ledge of the FOXP2-dependent molecular networks has 
enabled the identification of brain regions and pathways 
that this gene may influence. Although FOXP2 mutations 
seem to contribute to only a relatively small number of 
language disorder cases, it seems likely that variations in 
the  genes  it  controls,  such  as  CNTNAP2,  may  be 
implicated  in  common  forms  of  language  impairment. 
Thus, as our understanding of downstream targets grows, 
so will our list of potential candidate genes for SLI. The 
association  of  CNTNAP2  variations  with  an  array  of 
developmental  disorders  indicates  that  alternative 
deficits may arise from the dysfunction of a neurological 
net  work,  demonstrating  the  complexity  of  brain 
develop  ment processes.
Although  the  expression  of  FOXP2  seems  to  be 
particularly important for neurological mechanisms rele-
vant to motor skills, we predict that ATP2C2 and CMIP 
are likely to be involved in memory-related circuits. Thus, 
although  language  is  unique  to  humans,  we  should  not 
necessarily  expect  the  pathways  underlying  it  to  be 
exclusive  to  humans.  Processes  such  as  memory  and 
motor skills have key roles in language development, but 
they are certainly not specific to, and may not be com-
pletely  essential  for,  language  acquisition.  Rather,  we 
expect  that  a  variety  of  pre-existing  and  diverse  neuro-
logical  pathways  have  been  adapted  to  promote  the 
development of human language [79]. Characterization of 
these pathways and the way they overlap and interact will 
be an enormous task but one that is becoming increasingly 
feasible thanks to advances in genetic techniques. Given 
the  expected  complexity  of  such  pathways,  it  seems 
unlikely  that  the  identification  of  genetic  susceptibility 
factors will ever lead to the dis  covery of a ‘cure’ for SLI. 
Nonetheless,  this  is  a  worth  while  endeavor,  as  a  better 
understanding  of  the  causes  of  SLI  will  allow  the 
development of better diagnostic systems and therapies for 
affected  individuals.  Furthermore,  it  is  clear  that  the 
achievement  of  the  ultimate  goal  -  the  elucidation  of  a 
genetic network underpinning language processes - will 
have an impact on our understanding not only of language 
impairment  and  acquisition,  but  also  of  human 
development, brain function and the neuropathology of 
associated develop  mental disorders.
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